Table 2. Characteristics and response to treatment in patients with stable disease greater than 2 months.
| Age | Gender | Ethnicity/Race | Performance Status | Histology | # prior lines of therapy | EGFR status | KRAS status | ALK status | Best Response | Duration of SD (months) | OS (months) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 64 | F | Caucasian | 1 | Adeno | 1 | WT | WT | WT | SD | 10.5 | 34.9 |
| 72 | F | Caucasian | 1 | Adeno | 1 | WT | WT | WT | SD | 10 | 19.5 |
| 69 | M | Caucasian | 1 | Adeno | 2 | WT | WT | WT | SD | 8 | 22.5 |
| 77 | M | Caucasian | 1 | Squamous | 2 | WT | WT | ND* | SD | 6.25 | 33.4 |
| 74 | M | Caucasian | 1 | Adeno | 3 | WT | WT | WT | SD | 6 | 8 |
| 63 | M | Hispanic | 1 | Adeno | 3 | WT | ND | ND | SD | 6 | 9.25 |
| 71 | F | Caucasian | 1 | Squamous | 3 | ND | ND | ND | SD | 4.25 | 5.75 |
| 68 | F | African American | 0 | Squamous | 3 | ND | ND | ND | SD | 4 | 13.5 |
F, female; M, male; WT, wildtype; ND, not determined; SD, stable disease; OS, overall survival